The Patent Finder
EP

Ellodi Pharmaceuticals, L.P.

First filing 2010
OverviewNotableFeesChangesFamiliesPatent listSources & methods

19 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Oct 2030. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
8
Ending by 2030
Oct 2030
Next term end
4
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 27, 2026
    The maintenance fee for Methods of Treating Eosinophilic Esophagitis (US 11,684,571) comes due Dec 27, 2026. Unpaid by Jun 28, 2027, it lapses early.
  • 1 fee due May 12, 2027
    The maintenance fee for Corticosteroid Containing Orally Disintegrating Tablet Compositions for Eosinophilic Esophagitis (US 10,471,071) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
  • 1 fee due Aug 13, 2027
    The maintenance fee for Methods of Treating Eosinophilic Esophagitis (US 11,896,710) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.
  • 1 fee due Oct 28, 2027
    The maintenance fee for Orally Administered Corticosteroid Compositions (US 10,632,069) comes due Oct 28, 2027. Unpaid by Apr 28, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 9,387,167Orally Administered Corticosteroid Compositions
In force
 · High confidence
In forceHigh confidence
US 9,486,407Orally Administered Corticosteroid Compositions
In force
 · High confidence
In forceHigh confidence
US 9,849,084Orally Administered Corticosteroid Compositions
In force
 · High confidence
In forceHigh confidence
US 10,632,069Orally Administered Corticosteroid Compositions
In force
 · High confidence
In forceHigh confidence
US 11,246,828Orally Administered Corticosteroid Compositions
In force
 · High confidence
In forceHigh confidence
US 11,266,598Orally Administered Corticosteroid Compositions
In force
 · High confidence
In forceHigh confidence
US 12,290,598Orally Administered Corticosteroid Compositions
In force
 · High confidence
In forceHigh confidence
US 8,771,729Orally Administered Corticosteroid Compositions
In force
 · High confidence
In forceHigh confidence
US 10,471,071Corticosteroid Containing Orally Disintegrating Tablet Compositions for Eosinophilic Esophagitis
In force
 · High confidence
In forceHigh confidence
US 11,166,961Corticosteroid Containing Orally Disintegrating Tablet Compositions for Eosinophilic Esophagitis
In force
 · High confidence
In forceHigh confidence
10 of 19 patents shown.
Pro members see all 19.
Pro members: see all 19 patents
Also on record, not counted in the 19: 1 patent ended · 7 applications pending · 5 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited